NCT02440672Active, not recruitingNot Applicable
A Prospective, Non-randomized, Single Cohort, Multicenter Study to Evaluate the Clinical Outcomes of Total Knee Arthroplasty (TKA) Using the JOURNEY™ II CR Total Knee System
Smith & Nephew, Inc.18 sites in 3 countries170 target enrollmentStarted: September 1, 2015Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Smith & Nephew, Inc.
- Enrollment
- 170
- Locations
- 18
- Primary Endpoint
- Non-inferiority of the survival rate of the J II CR TKS with the reference survival rate of a literature reference at 5 and 10-years post-operatively
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of the JOURNEY™ II CR Total Knee System in subjects with degenerative joint disease (DJD) requiring primary total knee replacement.
Detailed Description
This is a prospective, non-randomized, single cohort, multicenter study to evaluate the clinical outcomes of TKA using the JOURNEY™ II CR Total Knee System in subjects with degenerative joint disease (DJD) requiring primary total knee replacement. One hundred and seventy (170) subjects will be enrolled at up to 18 clinical sites globally. Follow-up clinical assessments will be performed at 3 months, 1 year, 2 years, 5 years, and 10 years post-operatively.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 22 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects MUST meet ALL of the following criteria for inclusion in the study:
- •Has signed the IRB/EC approved ICF specific to this study prior to study participation
- •Is a male or female ≥ 22 and ≤ 75 years of age presenting with degenerative joint disease (DJD) of the knee
- •Is a candidate for primary total knee arthroplasty with the JOURNEY™ II CR Total Knee System due to DJD, defined by one of the following:
- •Post-traumatic arthritis
- •Osteoarthritis
- •Degenerative arthritis
- •Is able to read and understand the approved Informed Consent Form and Patient Reported Outcome (PRO) assessments (written and oral)
- •Is in general good health (as determined by the Investigator) based on screening assessments and medical history
- •Is independent, ambulatory, and can comply with all post-operative evaluations
- •plans to be available through ten (10) years post-operative follow-up
Exclusion Criteria
- •1. Subjects will be excluded from the study, if they meet ANY one (1) of the following criteria:
- •Any of the following conditions in the index joint:
- •does not require patella resurfacing
- •has received a TKA or unicondylar arthroplasty
- •has inadequate bone stock to support the device (e.g. severe osteopenia/osteoporosis)
- •Any of the following conditions in the contralateral joint:
- •has enrolled in the study for the contralateral knee
- •has received TKA as a revision for a failed total or unicondylar knee arthroplasty
- •has received a primary TKA or unicondylar knee arthroplasty that is not fully healed and well-functioning, as determined by Investigator
- •Any of the following conditions of the hip:
- •received contralateral or ipsilateral revision hip arthroplasty
- •has ipsilateral hip arthritis resulting in flexion contracture
- •has received a ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty, that is not fully healed and well-functioning, as determined by Investigator
- •Has diagnosis of an immunosuppressive disorder
- •Has presence of malignant tumor, metastatic, or neoplastic disease
- •Has family history of severe osteoporosis/osteopenia
- •Has a known allergy to study device or one or more of its components
- •Has conditions that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, lupus, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease)
- •Is receiving medication for the diagnosis of fibromyalgia
- •has a lower extremity condition causing abnormal or restricted ambulation (e.g. ankle fusion, ankle arthroplasty, previous hip fracture)
- •Is pregnant or plans to become pregnant during the study
- •Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study and complete PROs, as determined by Investigator
- •Has a BMI > 40
- •Is currently enrolled in or has participated in another investigational drug, biologic, or device study within 3 months of enrollment
- •Is currently involved in personal injury litigation or a worker's compensation claim
- •Is facing current or impending incarceration
- •Is known to be at risk for lost to follow-up, or failure to return for scheduled visits
Arms & Interventions
Device:JOURNEY™ II CR Total Knee System (J II CR TKS)
Subjects having TKA with JOURNEY™ II CR Total Knee System
Intervention: JOURNEY™ II CR Total Knee System (J II CR TKS) (Device)
Outcomes
Primary Outcomes
Non-inferiority of the survival rate of the J II CR TKS with the reference survival rate of a literature reference at 5 and 10-years post-operatively
Time Frame: Up to 10 year post-operative analysis
Equivalence in 1 year post-operative mean Range of Motion (ROM) in subjects receiving the J II CR TKS as compared to the literature reference mean ROM
Time Frame: 1 year post-op analysis
Secondary Outcomes
- Safety Endpoints: Manipulations under anesthesia(Pre-Op to 10 yrs)
- Health Economic Endpoints: Discharge destination(s)/length of stay(30, 60, and 90 days)
- Health Economic Endpoints: Concomitant medications/procedures associated with the knee(30, 60, and 90 days)
- Clinical Outcomes: Self-Administered Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty (SAPSS(Pre-Op to 10 yrs)
- Health Economic Endpoints: Unscheduled professional visits (e.g. hospital, emergency room, orthopedic clinic, primary care physician)(30, 60, and 90 days)
- Safety Endpoints:Adverse events, to be evaluated by type, frequency, severity, and relatedness to the study treatment.(Pre-Op to 10 yrs)
- Clinical Outcomes: 2011 Knee Society Score (2011 KSS) clinical evaluation(Pre-Op to 10 yrs)
- Health Economic Endpoints : Physical therapy visit quantification/duration(30, 60, and 90-day hospital re-admission rate)
- Safety Endpoints: Radiographic analysis(Pre-Op to 10 yrs)
- Clinical Outcomes: EuroQol 5D (EQ-5D) scale(Pre-Op to 10 yrs)
Investigators
Study Sites (18)
Loading locations...
Similar Trials
Completed
Unknown
A Prospective, Multicenter, Study to Evaluate the Safety and Effectiveness of the JOURNEY II XR Total Knee System with VERILAST TechnologyThe subject components are indicated for total knee arthroplasty performed for rheumatoid arthritis, post-traumatic arthritis, osteoarthritis, degenerative arthritis, failed osteotomies, or failed unicompartmental replacement.JPRN-UMIN000034044Smith & Nephew KK106
Active, not recruiting
Not Applicable
JOURNEY II XR Safety and Effectiveness PMCFUnilateral Post-Traumatic Osteoarthritis of KneeDegenerative Arthritis Peripheral JointRheumatoid Vasculitis With Rheumatoid Arthritis of KneeFailed Unicompartmental ReplacementFailed OsteotomiesKnee OsteoarthritisNCT03136887Smith & Nephew, Inc.176
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus PatientsDiabetes MellitusNCT01370707HK inno.N Corporation187
Terminated
Phase 2
An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT00941707Johnson & Johnson Pharmaceutical Research & Development, L.L.C.86
Completed
Phase 2
A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug TherapyArthritis, RheumatoidNCT01597739Janssen Research & Development, LLC96